Autologous Cell Therapy Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 15.90 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Autologous Cell Therapy Market Analysis
The Autologous Cell Therapy market studied was anticipated to grow with a CAGR of 15.9%, during the forecast period.
The growth of the market is attributed to the rising number of clinical trials and the growing adoption of cell therapies globally. In the context of COVID-19, government organizations in various countries, research institutes, and many biotech and pharmaceutical firms are focusing on effective and rapid technologies for the fast diagnosis of COVID-19. Additionally, the increasing clinical trials for using the treatment of COVID-19 using autologous cell therapies are expected to contribute to the growth of the market. For instance, as per the clinical trails.gov in 2022, A clinical study was started from January 2020 to March 2021 to study the population of all Swedish Citizens treated with autologous hematopoietic stem cell transplantation for COVID-19 positive patients. The positive results from such studies can lead to the development of new therapies for COVID-19 and thus can propel the growth of the market.
The major factors attributing to the growth of the autologous cell therapy market are the rising incidence of chronic diseases such as autoimmune diseases, cancer, a blood disorder, and others. A rise in the population suffering from chronic diseases is also propelling the demand for market growth. As per the report of the International Agency for Research on Cancer published GLOBOCAN 2020 report which estimated the incidence of 36 cancer in 185 countries, globally, there were an estimated 19,292,789 new cases of cancer diagnosed in 2020 all over the world. Of the total diagnosed cancer cases, 10,065,305 cases were reported in males and 9,227,484 cases were reported in females. the incidence of cancer cases in males was expected to reach 15,585,096 by 2040 and 13,302,846 in females by 2040. Such an increasing incidence of cancer among the global population is expected to drive the growth of the market. Common chronic blood disorders include anemia, bleeding disorders such as hemophilia and blood clots, and blood cancers such as leukemia, lymphoma, and myeloma. As per the May 2022 update by the Center for Disease Control and Prevention, sickle cell disease (SCD) affects approximately 100,000 Americans. It occurs among about 1 out of every 365 Black or African American births. Effective treatment is the best way to protect the life of a patient with blood cell disorder. And other factors are playing crucial roles in taking the autologous cell therapy market to the next level, among them are ongoing drug developments for new applications which are expected to further propel the growth of the autologous cell therapy market. The growth of the market is attributed to the rising number of clinical trials and the growing adoption of cell therapies globally in the forecast period.
However, systemic immunological reactions possibility and expensive practise, product and high capital investment are expected to restrain the growth of the market over the forecast period.
Thus the above-mentioned factors are expected to drive the growth of the market during the forecast period.
Autologous Cell Therapy Market Trends
This section covers the major market trends shaping the Autologous Cell Therapy Market according to our research experts:
Musculoskeletal Disorder Segment is Expected to Hold the Largest Market Share in the Autologous Cell Therapy Market
The musculoskeletal disorders segment is expected to drive the demand for autologous cell therapy for effective treatment. The rise in musculoskeletal disorders among the global population is expected to contribute to the growth of the studied segment along with the launch of innovative autologous cell therapies.
The Key facts published by World Heart Organization (WHO) in February 2021 reported that about 1.71 billion people have musculoskeletal conditions worldwide. Musculoskeletal conditions are the leading contributor to disability worldwide, with low back pain being the single leading cause of disability in 160 countries. Among musculoskeletal disorders, low back pain causes the highest burden with a prevalence of 568 million people. According to the same source, the aging population in the world is increasing, and the number of people with musculoskeletal conditions is rapidly increasing. Musculoskeletal conditions are also the biggest contributor to years lived with disability (YLDs) worldwide with approximately 149 million YLDS, accounting for 17% of all YLDs worldwide. Thus, the increasing number of musculoskeletal disorders is expected to increase the need for effective therapies such as autologous therapies, thereby contributing to the growth of the market.
Also, according to Work-Related Musculoskeletal Disorders statistics in Great Britain, in 2021, 470,000 people suffer from work-related musculoskeletal disorders which are new or long-standing in the year 2020-2021. In the future, such incidence of musculoskeletal disrders conditions are expected to drive the demand for effective therapies which will accelerate the segment growth in the forecast period.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America is expected to dominate the overall autologous cell therapy market, throughout the forecast period. This is owing to factors such as the rising incidence of chronic diseases such as cancer, a blood disorder, autoimmune diseases, and other diseases, and the availability of advanced healthcare infrastructure among the major factors.
For instance, according to the American Cancer Society's report 2022 over 1.9 million new cancer cases are expected to be diagnosed in the United States in 2022. Additionally, 80% of the people diagnosed with cancer in the United States are 55 years of age or older and 57% are 65 or older Thus, due to the high prevalence of cancer, and the rising affected geriatric population, the demand for diagnostics and treatment is also high in the country which is expected to drive the growth in the studied market in the United States.
As per an October 2021 update by the National Cancer Institute, acute myeloid leukemia is the most common type of acute leukemia in adults. In addition, as per the 2021 statistics by the Leukemia & Lymphoma Society, an estimated 397,501 people are living with or in remission from leukemia in the United States. The growing burden of blood disorders such as leukemia is expected to surge the demand for autologous cell therapy, thereby contributing to the growth of the market in this region
Autologous Cell Therapy Industry Overview
The autologous cell therapy market is moderately competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. And some prominent players are vigorously making acquisitions and joint ventures with the other companies to consolidate their market positions across the globe. Some of the companies which are currently dominating the market are Vericel Corporation, Pharmicell Co., Inc., Holostem Terapie Avanzate S.r.l., Lineage Cell Therapeutics, Inc., and Opexa Therapeutics.
Autologous Cell Therapy Market Leaders
Vericel Corporation
Pharmicell Co., Inc.
Holostem Terapie Avanzate S.r.l.
Opexa Therapeutics
Lineage Cell Therapeutics, Inc.
*Disclaimer: Major Players sorted in no particular order
Autologous Cell Therapy Market News
- In April 2022, Aspen Neuroscience, Inc., launched the first patient screening study of its kind, working with multiple clinical screening sites in the United States. The company's Trial-Ready Cohort Study is a preliminary step to filing an Investigational New Drug (IND) application with the United States Food & Drug Administration for ANPD001 and investigation of iPSC-derived cell replacement therapies for Parkinson's disease.
- In April 2022, TreeFrog Therapeutics launched The Stem Cell SpaceShot Grant, accounting for USD 100,000 in research funding in the field of stem cell biology and regenerative medicine.
Autologous Cell Therapy Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidence of Chronic Diseases
4.2.2 Emphasis Increasingly on Drug Development for New Applications
4.3 Market Restraints
4.3.1 Systemic immunological reactions possibility
4.3.2 Expensive practise, product and high capital investment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Therapy
5.1.1 Autologous Stem Cell Therapy
5.1.2 Autologous Cellular Immunotherapies
5.2 By Application
5.2.1 Oncology
5.2.2 Musculoskeletal Disorder
5.2.3 Blood Disorder
5.2.4 Autoimmune Disease
5.2.5 Others
5.3 By Source
5.3.1 Bone Marrow
5.3.2 Epidermis
5.3.3 Others
5.4 By End User
5.4.1 Hospitals
5.4.2 Research Centers
5.4.3 Others
5.5 Geography
5.5.1 North America
5.5.1.1 The United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East and Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East and Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Vericel Corporation
6.1.2 Pharmicell Co., Inc.
6.1.3 Holostem Terapie Avanzate S.r.l.
6.1.4 Lineage Cell Therapeutics, Inc.
6.1.5 Opexa Therapeutics
6.1.6 BrainStorm Cell Therapeutics
6.1.7 Sangamo Therapeutics
6.1.8 Bayer AG
6.1.9 Daiichi Sankyo Co., Ltd
6.1.10 Takeda Pharmaceutical Co., Ltd
6.1.11 Sumitomo Chemical Co., Ltd
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Autologous Cell Therapy Industry Segmentation
As per the scope of the report, autologous cell therapy (ACT) is a groundbreaking therapy that uses the cells of an individual that are grown and expanded outside of the body and reintegrated into the donor. The autologous cell therapy market is segmented by Therapy (Autologous Stem Cell Therapy and Autologous Cellular Immunotherapies), Application (Oncology, Musculoskeletal Disorder, Blood Disorder, Autoimmune Disease and Others), Source (Bone Marrow, Epidermis and Others), End User (Hospitals, Research Centers and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| By Therapy | |
| Autologous Stem Cell Therapy | |
| Autologous Cellular Immunotherapies |
| By Application | |
| Oncology | |
| Musculoskeletal Disorder | |
| Blood Disorder | |
| Autoimmune Disease | |
| Others |
| By Source | |
| Bone Marrow | |
| Epidermis | |
| Others |
| By End User | |
| Hospitals | |
| Research Centers | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Autologous Cell Therapy Market Research FAQs
What is the current Global Autologous Cell Therapy Market size?
The Global Autologous Cell Therapy Market is projected to register a CAGR of 15.90% during the forecast period (2024-2029)
Who are the key players in Global Autologous Cell Therapy Market?
Vericel Corporation, Pharmicell Co., Inc., Holostem Terapie Avanzate S.r.l., Opexa Therapeutics and Lineage Cell Therapeutics, Inc. are the major companies operating in the Global Autologous Cell Therapy Market.
Which is the fastest growing region in Global Autologous Cell Therapy Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Autologous Cell Therapy Market?
In 2024, the North America accounts for the largest market share in Global Autologous Cell Therapy Market.
What years does this Global Autologous Cell Therapy Market cover?
The report covers the Global Autologous Cell Therapy Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Autologous Cell Therapy Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Autologous Cell Therapy Industry Report
Statistics for the 2024 Autologous Cell Therapy market share, size and revenue growth rate, created by Mordor Intelligenceā¢ Industry Reports. Autologous Cell Therapy analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
